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Introduction 
 
Epidemiology and pathogenesis: 
Breast cancer is the commonest cancer occurring in women in Europe (1). In Switzerland, 
between 2003 and 2007 they were approximately 5000 new cases per year (2) and it is the 
primary cause of cancer related death in women, with a mortality rate of 19.2% (2). Incidence 
remained stable until the introduction of mammography screening in the 80s (3); an increased 
ensued, as mammography detected instances of carcinoma in situ and small invasive 
carcinomas that would have remained undiscovered without this method (3). Conversely, 
cases of advanced stage carcinoma decreased (figure 1) and currently less than 10% of cases 
display metastatic disease at initial presentation (3). This, combined with the availability of 
modern therapies, has led to the decrease in breast cancer mortality in the last decade (3,4). 
                              
Figure 1: Change in incidence depending on stage of breast cancer  from 1983 to 1996. (SEER Cancer Statistics 
Review, http://seer.cancer.gov/.)(3) 
Breast cancer is a multifactorial disease arising from interactions between genetic, 
reproductive and environmental factors (5). Reproductive risk factors include the combined 
oral contraceptive pill, early menarche, advanced age of first pregnancy, nulliparity, hormonal 
replacement therapy and late menopause. Obesity, unhealthy diet, smoking, alcohol 
consumption and lack of exercise rank amongst the environmental factors (5). Inherited risks 
comprise of age, specific mutations in BRCA1/2, and familial history of cancer (5). It is 
believed that these interactions lead to the development of cancer via various carcinogenesis 
pathways (through a series of molecular alterations at the cellular level) resulting in the 
evasion of growth-inhibition signals, evasion of apoptosis and spread of breast epithelial cells 
(6). However no common genetic or functional changes can be consistently observed in every 
breast cancer investigated (3). 
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Breast cancer molecular subtypes: 
The majority of breast cancers (more than 95%) are adenocarcinomas. Classification of breast 
cancer has been conventionally based upon histology, following the WHO 2003; Tumours of 
the Breast and Female Genital Organs recommendations (32). It divides breast tumours into 
two categories: infiltrative carcinoma and in situ (3). DCIS (ductal carcinoma in situ) and 
LCIS (lobular carcinoma in situ) constitute the latter category. Invasive breast malignancy is 
then subclassified as follows: ductal carcinoma (60-75% of all invasive carcinomas), lobular 
carcinoma (8%), and the remaining 15% which consist of much rarer tumours such as tubular, 
medullary, mucinous and papillary types (32). In total, 19 categories have been described. 
Recently, by using microarray technology to define gene expression of breast cancer, four 
different subclasses have been described: luminal A, luminal B, HER2+, triple negative 
(8,12). This technique uses the association of gene clusters to define the subtypes (8). It has 
been shown that clinically these subtypes each have a distinct natural evolution and 
progression (figure 2); each also responds differently to adjuvant treatment (9,11,12). It is 
thought that these features are indicative of distinctions in specific growth rate, intracellular 
signal pathways and cell composition, thus explaining breast cancer heterogeneity (9). This 
classification is now approved and is considered integral to the efficacious treatment of breast 
cancer (7,10).  
  
 
Figure 2: Survival plot of 294 breast 
cancer patients. A Kaplan-Meier 
survival plot of overall survival 
corresponding to 294 breast cancers 
from the publicly available UNC 
database is shown grouped by 
molecular subtype (11).  
 
 
 
 
 
Microarray is not utilised in the hospital setting however, with cost concerns dictating that the 
subtypes are evaluated by immunohistochemistry (10). Goldhirsch and al., consider this 
method as a valid surrogate for microarray technology (10). Those subclasses are defined 
according to oestrogen and progesterone receptor positivity, HER2 status and Ki-67 
(proliferation rate) (table 1) (10). The St-Gallen 2011 expert consensus created specific 
recommendations on how to classify breast tumours based upon the criteria mentioned above. 
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Table 1: breast cancer molecular subtypes: Definitions according to St-Gallen 2011 consensus 
 
 ER and/or PR  HER2 overexpressed Ki-67 
Luminal A Positive Negative Less 14% 
Luminal B Positive Negative High 
Luminal B Positive Positive Any value 
HER2+ Negative Positive Any value 
Triple negative Negative Negative Any value 
 
Adjuvant treatment:  
Management of breast cancer depends on a combination of several factors: tumour biology 
(molecular subtype, grade, hormonal receptors, HER2 status, proliferation rate and 
histological type); tumour stage (tumour size and axillary lymph node involvement); peri-
tumoural lymphovascular invasion; patient’s age and menopausal status (13-15). Adjuvant 
treatment consists of chemotherapy, radiotherapy, hormonotherapy and immunotherapy. 
Radiotherapy follows surgery in most cases to prevent local relapse. Hormone therapy should 
be given if the cancer is hormone receptor positive, and should be administered for at least 5 
years (14,16). Immunotherapy is used for women exhibiting HER2 overexpression. Adjuvant 
chemotherapy is used to destroy residual cancer cells believed to have survived elimination by 
surgery and radiotherapy (6). The goal is to avoid recurrence and the development of distant 
metastases, resulting in increased disease-free survival and overall survival (6,15). Analysis of 
several randomised control studies by the Early Breast Cancer Trialists’ Collaborative Group 
has shown reductions of 12% and 6% in 10 year mortality in the cohort under 50 years old, 
for node positive and node negative patients respectively (4). Women aged 50 to 69 years 
accrued reductions of 6% and 2%, for node positive and node negative patients respectively 
(4). 
However, over 70% of these patients would have been cured without the use of chemotherapy 
(7). These treatments are debilitating, with many secondary effects even leading to refractory 
secondary malignancies many years later. Also, some women who receive chemotherapy will 
still develop recurrence of the disease; 15% of early breast cancers which are classified as 
“low-risk” will eventually recur (7,15,20). Alighting upon the correct treatment regimen is 
especially problematic in early breast cancer, where differentiating those who will ultimately 
benefit from chemotherapy from those who will not is difficult for the clinician (7). 
 
Clinical tools in breast cancer: 
Tools have thus been developed to help the clinician make this decision, in the form of 
international guidelines, computer based techniques and genomic testing.  
6 
 
International guidelines were created by groups of experts, interpreting data from randomized 
controlled trials in a form suitable for the practice of evidence based medicine (14,15). 
However it is not an individualized based care.  
Computer-based tools, for example Adjuvant! Online, are easy-to-use online risk calculators 
tailored for clinical settings (15). They are founded on the same criteria as the guidelines, but 
are formulated to numerically express risk (15). These still need to be validated however, and 
current examples don’t take histology, node status or molecular subtype into consideration 
(15).  
The genomic tools include Oncotype Dx and Mamaprint. Oncotype Dx is a q-RT-PCR of a 21 
gene signature, giving a recurrence score to predict breast cancer recurrence (specifically for 
women with node-negative and ER positive tumours) (15). Mamaprint uses DNA microarray 
to investigate the expression of 70 particular genes, and is designed to predict the risk of 
development of metastases in early breast cancer (specifically for node-negative, ER 
positive/negative cancer type) (15). In the literature, these techniques have been proven to be 
more effective than the present guidelines and computer based techniques (15). A panel of 
experts at the 12
th
 annual St-Gallen conference in 2011 judged that Oncotype DX was helpful 
for decision making, while other predictive and prognostic factors didn’t appropriately 
indicate which management to choose (10). However, Mamaprint was adjudged not to be 
sensitive and specific enough to use in clinic (10). Randomized control studies have yet to be 
carried out to prove that Oncotype Dx can in fact assist in reducing mortality (15). The limits 
of these techniques include cost, their restricted application to only early stage breast cancer, 
variability in reproducing this technic for every tumours specimen and normalization of the 
results (15). 
 
The aforementioned tools may help in the direction of patient care but we believe there is a 
necessity for a more reliable and improved tool to assist the clinician in his judgment. 
 
Activator-protein 2 family: 
The human transcription factor activator-protein 2 alpha (AP-2 alpha) has been found to have 
a central role in the development of breast cancer (17,18). AP-2 alpha belongs to a family of 
proteins including AP-2 beta and gamma (19). AP-2 alpha is the most studied of AP-2 family 
subtypes in breast cancer (19). It is thought to have a tumour suppressor role in the breast, 
whereas the roles of the other members of this family are not yet well known (19). These 
52kda proteins recognize and bind specific DNA sequences on the target genes, enhancing or 
suppressing their expression (19). For example, p21, ER-alpha, and HER2 number amongst 
AP-2 alpha’s target genes, and all are essential in cell differentiation and growth (19). The 
general role of AP-2 in normal tissue was studied by using knock-out mouse trials, showing 
that mice lacking AP-2 presented with abnormal organogenesis and died at birth or soon after 
(19).  
AP-2 alpha’s role, localisation (nuclear vs cytoplasmic), regulation of ER, and its link to 
HER2 overexpression with regard to breast cancer are not yet well established (19). Some 
studies link a decrease in nuclear AP-2 alpha with more aggressive cancer types (17-19). 
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However, many current studies are contradictory in their findings (19). Pellikainen and 
Kosma suggested that one possible cause could be that the immunoshistochemical method 
used was not reliable, as the antibodies utilised were not specific enough (19). They also 
suggested that it was because AP-2 protein in vivo regulators could not be studied as 
accurately, results could be difficult to interpret (19). It is possible to study AP-2 alpha 
activity via a new method called protein-binding microarray (PBM) (17). Proteins, in this case 
AP-2 alpha, are put in contact with double stranded DNA sequences fixed on a microarray
 
(18). This technique allows the detection of protein binding on specific DNA sequences (18). 
This method has been demonstrated to be reliable and highly sensitive
 
(17). An initial study 
done at the University of Lausanne demonstrated that AP-2 alpha binding on DNA could have 
a better prognostic value than classic molecular diagnosis, and may redistribute the subtype 
classification (24). Now, there is a need to repeat this trial with a larger breast cancer sample 
size and a more robust microarray.  
 
Objectives: 
My objective is to create an anonymous database from clinical and pathologic data, to be used 
to correlate results from the PBM with the patient’s follow-up. Then it would be to amplify by 
PCR some targets of AP-2 alpha to be added on a custom microarray. This custom microarray 
will be used to test protein extract from breast tumours samples selected from the database 
previously made.   
In parallel, RNA will be extracted from breast tissues and quantitative RT-PCR will be done 
in order to correlate the AP-2 alpha binding activity on specific targets detected by PBM with 
the transcriptional level of those targets.   
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Method and materials 
 
Patient selection: 
One hundred mastectomy/tumeroctomy surgical samples were selected from the database of 
the pathology institute to carry out the trial. The specimens used were taken between 2000 
and 2005, so as to have at least 5 years of clinical background information. Specimens were 
of various molecular subtypes (luminal A, luminal B, HER2+, triple negative) and also from 
breast tissue adjacent to the tumour. Healthy tissue obtained at mammoplasty was used as a 
control.  All tissue samples were flash frozen and preserved at -80 C° to protect the cells’ 
integrity (proteins in particular). Surgical samples and documentation were rendered 
anonymously before being processed by the lab.  
Samples were selected and classified with regard to their respective predictive and prognostic 
factors, and added to a spreadsheet. Two different charts were formulated: the first for 
pathological data and the second for clinical data.  
Pathological information was classified according to the following categories: date of birth, 
type of surgery (tumeroctomy or mastectomy), where the operation was performed, date of 
operation, single or multifocal tumours, tumour size, number of sentinel lymph nodes 
analysed, number of lymph nodes analysed, number of positive lymph nodes (metastasis, 
micrometastasis, isolated tumour cell), histological type of the tumour, histological type of the 
lymph node, grade (Elston-Ellis), lymphovascular invasion, ER%, PR%, HER2 
overexpression, methodology used to detect HER2, and proliferation rate (Ki-67). 
Clinical information was classified according to the following categories: date of birth, date of 
diagnosis, menopausal status, chemotherapy (type, number of cycles), hormonotherapy (type, 
dosage, time), radiotherapy (local, loco regional+/- boost), date of most recent oncology clinic 
appointment, date of most recent hospital admission, recurrence, distant metastasis (when, 
where, histological type), new tumour, and death (cause).    
 
Frozen tissue and histological studies: 
Surgically removed tumours were conserved at -80 C°. Before extraction of protein and RNA, 
each specimen was cut, using cryostat, into sections of 30µm and 7µm, in the following 
sequence: (1)x7µm section superiorly – (30)x30µm sections – (1)x7µm section medially – 
(30)x30µm sections – (1)x7µm section inferiorly. The 30µm sections were collected in 
Eppendorf tubes and saved for protein and RNA extraction. The 7µm sections were placed on 
histology slides and stained with HE, following the HE protocol (see appendix 1). Cancer 
cells were detected on these slides using microscopy, thus verifying that cancer cells were 
present at throughout the sample, at these three levels, superiorly, medially and inferiorly. 
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Preparation of target genes for custom based PBM: 
Around 50 AP-2 alpha targets genes were selected for creating custom-made PBM. The 
following four target genes required amplification for spotting: ESR1, FABP5, WASF, TAF. 
Each of these genes was amplified and cloned in plasmids, pCR8®/GW/TOPO (Invitrogen), 
as described previously (18). For PCR amplification their respective annealing temperatures 
were of 62 C°, 58 C°, 58 C°, 60 C°. PCR solution was prepared following manufacturer’s 
recommendations (Qiagen). Briefly, 250µL of solution contained 0.5 µL miniprep DNA, 2.5 
µL primer 1 (100μM), 2.5 µl primer (100μM), 2.5 µL 10x tampon, 50 µL Q solution, 20 µL 
dNTP mix (2.5mM each), 1.25 µL high-fidelity Taq polymerase (Qiagen), 1.25 µL Taq 
polymerase, 147 µL water. A PCR programme was accomplished as follows : 95 C° for 10 
minutes; 95 C° for 30 seconds; annealing temperature for 30 seconds; 72 C° for 1minute and 
30 seconds, cycling through denaturation, annealing and extension for 35 cycles; 72 C° for 10 
minutes and 10 C° for forever.  
 
PCR products were electrophoresed in 1% agarose gel. The gel was prepared as a mix of 2 g 
agarose powder with 200 ml TAE and 20μl of SYBR safe DNA gel stain. The mix was then 
poured on an electrophoresis plate. Agarose fluorescents parts were then collected by cutting 
the gel under ultraviolet light source. PCR products were purified by centrifugation using 
Wizard SV gel and PCR Clean-Up System (Promega) (see appendix 2). 
The solution was then analysed using the nanodrop 3300 (Micro-Volume Full-Spectrum 
Fluorospectrometer) to quantify the DNA.   
 
Total RNA extraction and Reverse Transcription (RT): 
RNA extraction was performed on frozen tissue after cryostat cut as explained above, in five 
samples of luminal A, five luminal B, five triple-negative and 3 HER2+ samples, using the 
Trizol Reagent protocol (Invitrogen, San Diego, CA) (see appendix 3) . RNA purity was 
analysed using the nanodrop.  Reverse transcription was performed using a total of 500 ng of 
RNA to synthetize cDNA in a 33 µL total volume reaction (20 µL RNA + DTT 1µL, Primer 
1µL, Bulk first-strand reaction mix) with the GE Healthcare first-strand cDNA synthesis kit. 
 
Quantitative real-time PCR: 
AP-2 alpha binding activity was studied using a PBM with a H-6K promoter chip Avi-HU 
Pro6k lot (Aviva Systems Biology, San Diego, USA) containing 6000 genes. Selected genes 
of interest were observed, comparing the level of binding of the transcriptor factor between 
normal tissue and neoplastic tissue. These genes included: ER alpha and beta, PR, HER2, 
MMP2, MMP9, ANXA1, WWOX, and then one gene for each molecular subtype category 
that is unique to that subtype (table 2). Previous published studies were consulted to choose 
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appropriate gene primers. Primers were inputted to the website of UCSC genome 
bioinformatics for validation. Applied Bio system 7900 was used to carry out the real-time 
PCR in triplicate for each sample using light SYBR green master mix following manufacturer 
instructions (Roche). Control gene’s (β-actin, GAPDH, 18s) activity level was used as a 
reference for data normalization. Genes’ reverse and forward primers are described as 
followed (table 3). 
 
Table 2: The 15 genes selected from the 50 to which AP-2 alpha binds 
 
 
Table 3: Real-time quantitative PCR was made using the following primers: 
Gene Gene primers (For/Rev)  
(5′→3′) 
  
AP2 alpha F: CGA TCC AGA GCT GCT TGA CC 
R: GAG CCT CAC TTT CTG TGC TTC TC 
ERBB2 F: TCC TGT GTG GAC CTG GAT GAC 
R: CCA AAG ACC ACC CCC AAG A 
β-ACTIN F: TCC TTC CTG GGC ATG GAG 
R: AGG AGG AGC AAT GAT CTT GAT CTT 
GAPDH F: TTG TCA AGC TCA TTT CCT GG 
R: TGA TGG TAC ATG ACA AGG TGC 
18s F: CAA CTT TCG ATG GTA GTC G 
R: CCT TCC TTG GAT GTG GTA 
ER alpha F: TGG GCT TAC TGA CCA ACC TG 
R: CCT GAT CAT GGA GGG TCA AA 
PGR F: CGC GCT CTA CCC TGC ACT C 
R: TGA ATC CGC CCT CAG GTA GTT  
ANXA1 F: AGG GTG ACC GAT CTG AGG AC 
R: CTG GTG GTA AGG ATG GTA TTG A 
WWOX F: GAG CTG CAC CGT CGC CTC TCC CCA C 
R: TCC CTG TTG CAT GGA CTT GGT GAA AGG C 
MMP2 F: CCC TGT CAC TCC TGA GAT CTG C 
R: CAC AGT CCG CCA AAT GAA CC 
MMP9 F: CCA CCA CAA CAT CAC CTA TTG G 
Genes Breast cancer-associated 
18s  
Control genes β-ACTIN 
GAPDH 
AP-2 alpha  
 
Common to all 
ANXA1 
WWOX 
MMP2 
MMP9 
ER alpha Common to luminal A/B 
PGR 
ERBB2 Common to HER2+/luminal B 
EDG5 HER2+ 
RAP2B Triple negative 
TACR1 Luminal A 
PON2 Luminal B 
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R: ACT GGA TGA CGA TGT CTG CG 
EDG5 F: GCC TCT CTA CGC CAA GCA TTA 
R: TTG AGC GGA CCA CGC AGT A 
RAP2B F: AGC CAA ACG CAT CCG ACT CTC TAA 
R: CTG CAA AGA GCC ACA TTT CCA CCA 
TACR1 F: CTC AGA CCT CTC CCC AAA CA 
R: CAC AAT GAC CGT GTA GGC AG 
PON2 F: TGA GCT TCT TCC AAG TGT GAA TG 
R: AAA TGT GCC GGT CCA ACA G 
 
 
q-RT-PCR was performed on 16 tumour samples (5 luminal A, 3 luminal B, 3 HER2+, 5 
triple negative) and 5 normal tissue samples. 
 
Protein extraction: 
Protein extraction (AP-2 alpha) was achieved as described previously (22). Tissue specimens 
cut in 30 µm section that had been collected in the Eppendorf tubes were thawed on ice in a 
solution of 1X PBS (10 mM pH 7.4 Phosphate, 137 mM NaCl, 2.7 mM KCl) containing a 
cocktail of protease inhibitor (Roche complete protease inhibitor cocktail tablets, Roche) 
followed by centrifugation of the tissue fragments at 4 C° for 5 min at 3500 rpm. Pellets were 
recovered into 250 µL Low Salt Lysis Buffer (10 mM Tris pH 7.8, 1.5 mM MgCl2, 10 mM 
KCl) and incubation allowed on ice for 15 min. Cells were lysed by addition of 0.5 µL NP-40 
(0.02% masse/volume) and mixed by vortexing for 5 seconds. Nuclei were harvested by 
centrifugation for 5 min at 3500 rpm, 4 C° and the pellet washed with 300 µL Low Salt Lysis 
Buffer. After an additional centrifugation step (3500 rpm at 4C° for 5 min) the supernatant 
was taken off and the pelleted nuclei resuspended in 25 µL of High Salt Lysis Buffer (10 mM 
Tris pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 400 mM NaCl, NP-40 0,033% [masse/volume]). 
Samples were mixed by vortexing for 5 seconds and incubated on ice for 30 minutes with 
vortexing every 5-10 min in order to allow extraction of nuclear proteins. The supernatant 
containing the nuclear proteins was transferred into new coded tubes and diluted by adding 25 
µL of Low Salt Buffer to bring the final NaCl concentration to 200 mM and immediately 
frozen in liquid nitrogen. 
 
Protein-binding microarray assay:  
Protein-binding microarray assay was performed as described previously (18,22). Custom-
made PBMs were treated prior to use as follows: slides were washed twice for 2 minutes with 
1xTEN (40 mM Tris-HCL pH 7,5, 1 mM EDTA, 150 mM NaCl), then reduction of aldehydes 
was performed in the reduction solution (0.25% NaBH4 [masse/volume] in PBS 1X/EtOH 
25%) for 10 minutes, followed by two washes of 2 minutes with 1xTEN. Slides were then 
blocked in the blocking solution for 1 hour (5% skimmed milk in PBS 1X/0.05% Tween-20) 
followed by two final washes for 2 minutes with 1xTEN. Labeling of the DNA on the arrays 
was carried out as describe here: slides were pre-incubate with 1xPBS containing 100 µg/mL 
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adenosine monophosphate (AMP), followed by application of the DNA labeling mix (1x NEB 
buffer 4, 100 µg/mL AMP, 0.1 mM CoCL2, 0.2 µM ddNTP-Cyanine5 [Perkin Elmer], 0.02 
U/µL TdT [NEB]). After incubation for 1.5 hour at 37 C° in the absence of light, slides were 
washed twice for 2 minutes in 1xTEN and spun dry. 
AP2-binding reaction mix (2.5 mM Tris-Hcl pH 7.9, 15 mM KCl, 1 mM MgCl2, 0.025 mM 
EDTA, 12.5 µg/ml BSA, 0.05 % NP40 2 % [masse/volume] skimmed milk, 0.015 µg/µL 
poly-dIdC, 0.15 ng/µL purified GST-AP2α or 100 to 1000 ng/µL of protein from nuclear cell 
extract) was applied onto each array slide and incubated at room temperature (RT) in the 
absence of light for 1 hour. Slides were washed 5x3 minutes with 1x PBS supplemented with 
1 % (volume/volume) Tween 20, 3x5 minutes with 1x PBS containing 0.01 % 
(volume/volume) Triton-X-100 and spun dry. Next, the primary antibody (AP2-alpha (C-
18):sc-184, Santa Cruz Biotechnologies) was applied in 1x PBS supplemented with 2% 
skimmed milk, and incubated for 1 hour at RT in the absence of light. Slides were washed 3x5 
minutes with 1x PBS with 0.05 % (v/v) Tween 20, 3x5 minutes with 1x PBS with 0.01 % 
(volume/volume) Triton-X-100, before incubating with the secondary antibody (Cy3-labeled 
Alexa Fluor 546 goat anti-rabbit IgG, Molecular Probes) in 1x PBS supplemented with 2 % 
(masse/volume) skimmed milk for 1 hour at RT in the absence of light. This was followed by 
a final washing cycle (3x5 minutes with 1x PBS, 0.05 % [volume/volume] Tween 20, 3x5 
minutes with 1x PBS, 0.01 % [volume/volume] Triton-X-100 and once for 5 minutes with 1x 
PBS). The Agilent G2566AA scanner was used to detect the fluorescence and this later was 
analyzed using the GenePix Pro6 software.  
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Results 
 
Molecular subtypes:  
The pathological Institute of Lausanne referred 103 tumour samples for use in this study. Of 
these 103, 24 tumour specimens were excluded as clinical data was not available. Of the 79 
remaining, 49% were luminal A, 1% were luminal B, 9% were HER2+ and 8% were triple 
negative and 33% were of undetermined molecular subtype (figure 3).  
 
 
 
 
Figure 3: number of tumour samples depending on their molecular subtypes (LA= luminal A, LB= luminal B, 
HER2+, TN= triple negative, NA= undetermined). 
Classification of the specimens was performed according to hormonal status and HER2 
overexpression. This does not follow the St-Gallen recommendations (mentioned above), as it 
does not include the Ki-67 (MIB-1) parameter. 33% of samples remained of undetermined 
subtype as HER2 overexpression status was not routinely carried during the period in question 
(2000-2005).  
The mean age of patients was 65 years old and 73% of patients had reached menopause at 
time of diagnosis of breast cancer.  
25% of women developed metastasis, at an average time of 21.55 months post diagnosis.  
Incidence of metastasis in patients with different molecular subtypes was as follows: 20.5 % 
of luminal A, 0 % of luminal B, 50 % of triple negative, 42.9 % of HER2+, and 23.1 % of 
undetermined subtype (figure 4). Nearly half of the patients who developed metastasis had 
received chemotherapy, which was of various regime types. 
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Figure 4: number of patients who developed metastasis in the 5 years follow-up depending on their respective 
molecular subtype (LA= luminal A, LB= luminal B, HER2+, TN= triple negative, NA= undetermined).   
Chemotherapy was given to 43% of patients, with different regimes administered depending 
on the case. 11% of these 43% had received chemotherapy neoadjuvantly. 
Relapse-free survival rates were evaluated using a Kaplan-Meier analysis curve (figure 5). 
Relapse is here interpreted as any evidence of recurrence or metastasis. Undetermined tumour 
type samples were not taken into consideration. Triple negative molecular subtype reported 
the lowest disease free survival rate. However, the difference between the molecular subtypes 
did not show statistical significance (p-value = 0.246).  
 
 
Figure 5: relapse free survival curve based on the different molecular subtypes (LA= luminal A, LB= luminal B, 
HER2+, BL= triple negative, NA= undetermined).   
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Mortality rates could not be determined as cause of death was not always reported in the 
clinical files.   
  
PCR gene amplification: 
DNA quantity was analysed using the nanodrop samples of gene amplification.  Results using 
the nanodrop are recorded in table 4. 
Table 4 
Sample ID Ng/ul A260 A280 260/280 260/230 
ESRI 89.98 1.800 0.959 1.88 2.54 
FABP5 45.55 0.911 0.504 1.81 2.26 
TAF1 27.01 0.540 0.291 1.86 1.92 
WASF 61.81 1.236 0.675 1.83 2.96 
 
A280 and A260 represent the spectrum of absorbance of proteins and nucleic acids 
respectively (31). A230 represents the absorbance of contaminants. A260 and A280 ratio 
serves a control of purity of DNA. The ratio should be in the range 1.8-2.0; a decreased ratio 
could signify presence of contaminant (for example proteins). The A260/A230 ratio should be 
in the range 2.0-2.2 (31). For spotting samples were putted in a solution of 3XSSC/1.5M 
betaine at a final concentration of 80ng/ul. 
 
Histology of frozen tissue slides: 
 
        
  A                                                                       B 
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                                        C 
Figure 6: micrographs of normal breast tissue (A) (B) and tumour sample (C)  
Figure 6 displays micrographs of normal breast tissue (A) and tumour tissue (B) after staining 
with HE. (A) Normal breast tissue shows terminal duct lobular units that is surrounded by 
dense fibrous tissue. (B) Normal breast tissue shows a lactiferous duct with adipose tissue 
visible at the periphery. (C) Well differentiated invasive carcinoma. Cords of ductal epithelial 
cells are seen invading into the surrounding fibrous stroma. Image C source: Robbins Basic 
Pathology (3).   
 
Gene’s expression level: 
Of the three housekeeping genes (β-actin, GABDH and 18s), only β-actin was used. The 
amplification efficiencies of 18s were much greater than for other genes (a mean of 18 cycles 
compared to approximately 30 cycles for the remainder), thus rendering it unsatisfactory for 
normalisation. β-actin amplification efficiencies were similar to the target genes and so it was 
selected as our referenced gene. The delta-delta Ct method was used to assess gene expression 
level (30); this was calculated as fold change 2 (-Delta Delta C(T)) and normalized to β-actin 
gene level expression. 
RAP2B, TACR, MMP9, MMP2 and PGR were excluded as their expression levels (level of 
mRNA) could not be accurately analysed. For example, PGR expression levels were 
undetermined, as levels were under the detection threshold, even in tumour samples which 
expressed progesterone receptors. 
For each gene (AP-2 alpha, ER alpha, ERBB2, WWOX, PON2, ANXA1, EDG5) expression 
of mRNA was observed in normal tissue, giving us information on what occurs in non-
neoplastic cells. Table 5 displays mean fold change for each genes normalized to β-actin in 
normal tissue. Level of expression in normal tissue was used as a reference point to compare 
expression of the genes in the different subtype samples. 
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Table 5: mean gene’s fold change in normal tissue 
Genes Mean Min-Max level 
AP2alpha 1.137 0.013-1.377 
ERalpha 0 0 
WWOX 0.662 0.038-1.733 
PON2 0.270 0.035-1.316 
ANX1 0.390 0.151-1.074 
ERBB2 0 0 
EDG5 0.015 0-0.074 
 
AP-2 alpha mRNA levels in the different samples exhibited decreased expression in 
comparison to normal tissue. However, using non-parametric statistical analysis 
(Mann-Whitney test), this proved non-significant with p-values as follows: triple negative 
0.251, luminal A 0.175, luminal B 0.655, HER2+ 0.180 (Fig 7).  
 
 
 
 
Figure 7: fold change value of Ap2 alpha normalized to β-actin in the tumours and normal samples 
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Using the same method with the other target genes, statistical analysis revealed non-
significant correlation (p-values > 0.05) (Fig 8 A-E).     
 
          
       A                                                B                                              C 
 
D E 
Figure 8 (A-E): level of gene’s expression (EDG5, ER alpha, PON2, WWOX, AP-2 alpha, ERBB2, β-actin) as 
fold change normalized to β-actin in normal tissue and luminal A, luminal B, HER2+, triple negative tumour 
samples. 
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ER-alpha expression:  
 
 
Figure 9 : fold change value of ER alpha normalized to β-actin in the tumours and normal samples 
 
ER alpha expression results were in line with that expected (figure 9). HER3 and TN4 
samples were both classified molecularly as HER2 overexpression and triple negative, even 
though ER receptor expression was under 20%. It is uncertain if we can classify them as such, 
from a molecular standpoint.  
 
WWOX and AP-2 alpha expression: 
 
 
Figure 10: fold change value of WWOX normalized to β-actin in the tumours and normal samples 
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Analysis of the graph of fold change value correlation to gene expression of WWOX (figure 
10) reveals a surprisingly similar pattern to that with AP-2 alpha. Using a zero correlation test, 
the correlation was proven with a p-value < 0.05 and correlation of 0.846. This could mean 
there is a direct link between these two genes. 
 
Association between tumour characteristics and AP-2 alpha mRNA expression: 
The cut-off point to establish underexpression of AP-2 alpha in tumour samples compared to 
normal tissue was determined as the mean value of fold change of all the samples: 0.108. Two 
levels of underexpression were created. Of the 11 samples, 3 were slightly underexpressed 
(Ap2-) and 8 were more underexpressed (Ap2--). These two groups can be separated 
statistically using a paired-test, with a P-value of 0.036 making the difference significant. 
Using the same principle separation between groups were significant except for EDG5 and 
ERRB2 with p-values of 0.026 for ER alpha, p-value of 0.039 for WWOX, p-value of 0.0.44 
for PON2, p-value of 0.002 for ANXA1 and EDG5 p-value  of 0.216. 
We correlated the mRNA expression level of each sample with the tumours’ pathological 
characteristics and clinical data (menopausal status, tumour size, lymphovascular invasion, 
lymph nodes metastasis, histological grade, mastectomy, metastasis, chemotherapy and 
radiotherapy). LB5, HER5, LA3, TN3, TN4 were excluded as insufficient clinical data was 
available for each of these samples. No significant statistical difference (using Fisher’s exact 
test) was found between AP-2 alpha level of expression and pathological characteristics or 
clinical data. Results are shown in table 6. Correlation with for other genes was also neither 
significant. WWOX gene results were the same as AP-2 alpha. 
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B Wwox- Wwox-- P-value 
Menopaused    
Yes 3 6 0.509 
No 0 2  
Tumour size    
>2cm 1 4 0.455 
<2cm 2 4  
LVI    
Yes 0 4 0.212 
No 3 4  
Grade    
1 or 2 2 4 0.455 
3 1 4  
Mastectomy    
Yes 2 7 0.436 
No 1 1  
Lymph Nodes 
Metastasis 
   
Yes 0 4 0.212 
No 3 4  
Metastasis    
Yes 0 2 0.509 
No 3 6  
Chemotherapy    
Yes 0 4 0.212 
No 3 4  
Radiotherapy    
Yes 2 2 0.255 
No 1 6  
A Ap2- Ap2-- P-value 
Menopaused    
Yes 3 6 0.509 
No 0 2  
Tumour size    
>2cm 1 4 0.455 
<2cm 2 4  
LVI    
Yes 0 4 0.212 
No 3 4  
Grade    
1 or 2 2 4 0.455 
3 1 4  
Mastectomy    
Yes 2 7 0.436 
No 1 1  
Lymph Nodes 
Metastasis 
   
Yes 0 4 0.212 
No 3 4  
Metastasis    
Yes 0 2 0.509 
No 3 6  
Chemotherapy    
Yes 0 4 0.212 
No 3 4  
Radiotherapy    
Yes 2 2 0.255 
No 1 6  
D Anxa- Anxa-- P-value 
Menopaused    
Yes 3 6 0.509 
No 1 1  
Tumour size    
>2cm 2 3 0.455 
<2cm 2 4  
LVI    
Yes 0 4 0.106 
No 4 3  
Grade    
1 or 2 2 4 0.455 
3 2 3  
Mastectomy    
Yes 2 7 0.109 
No 2 0  
Lymph Nodes 
Metastasis 
   
Yes 2 2 0.212 
No 2 5  
Metastasis    
Yes 0 2 0.382 
No 4 5  
Chemotherapy    
Yes 1 3 0.424 
No 3 4  
Radiotherapy    
Yes 2 2 0.212 
No 2 5  
C Era+ Era++ P-value 
Menopaused    
Yes 2 7 0.655 
No 0 2  
Tumour size    
>2cm 0 5 0.273 
<2cm 2 4  
LVI    
Yes 1 6 0.509 
No 1 3  
Grade    
1 or 2 2 5 0.382 
3 0 4  
Mastectomy    
Yes 2 2 0.655 
No 0 7  
Lymph Nodes 
Metastasis 
   
Yes 0 4 0.382 
No 2 5  
Metastasis    
Yes 0 2 0.655 
No 2 7  
Chemotherapy    
Yes 0 4 0.382 
No 2 5  
Radiotherapy    
Yes 1 3 0.509 
No 1 6  
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Table 6 (A-E): correlation of genes’ expression level with pathological characteristic and clinical data 
 
Protein-binding microarray:  
During my internship at the laboratory, two tumour samples were tested with the PBM 
method. These were samples TN5 and LA3. The results for these two samples exhibited the 
molecular characteristics that we expected: Genes that represent the TN category exhibited 
the highest AP2 binding in PBM using TN5 protein extract, and genes that represent the LA 
category exhibited the highest AP2 binding using LA3 protein extract (figure 12). 
 
A   
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
ALL LA HER2 TN LB
AP-2  alpha target  
Luminal A 
E Pon2- Pon2-- P-value 
Menopaused    
Yes 4 6 0.636 
No 0 1  
Tumour size    
>2cm 2 3 0.455 
<2cm 2 4  
LVI    
Yes 0 4 0.106 
No 4 3  
Grade    
1 or 2 2 4 0.455 
3 2 3  
Mastectomy    
Yes 2 7 0.109 
No 2 0  
Lymph Nodes 
Metastasis 
   
Yes 2 2 0.212 
No 2 5  
Metastasis    
Yes 0 2 0.382 
No 4 5  
Chemotherapy    
Yes 1 3 0.424 
No 3 4  
Radiotherapy    
Yes 2 2 0.212 
No 2 5  
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B   
Figure 12: PBM results from luminal A (A) and triple negative (B) samples. Results are expressed as the mean 
of the mean of the log (protein/DNA) of each target gene to which AP-2 alpha was bound. AP-2 alpha target 
genes were classified depending on their association with the four molecular subtypes (e.g. LA represents the 
mean of the log (protein/DNA) of target genes found in luminal A type tumours. ALL represents genes that are 
common to the four subtypes. 
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Discussion  
 
Maximal data extraction from this study necessitates a more complete classification for the 
molecular breast subtypes; this requires determination of HER2 status and Ki-67. The 26 
samples which remained undetermined could significantly alter the results. In the literature 
42% of invasive carcinomas were found to be of luminal A subtype, 28% were luminal B, 6-
15% were triple negative, and 8-20% were HER2+ (25). In this study however, results are 
different due to both the undetermined samples and the small numbers involved.  
Luminal type cancers (luminal A>luminal B) have been previously shown to exhibit the best 
relapse free survival rates, with triple negative and HER2+ displaying shorter times to relapse 
(12). Our results do not display a significant difference regarding time to relapse between the 
different molecular subtypes. Also, the luminal B subgroup showed the best results for relapse 
free survival time as no recurrence or metastasis was found in the only patient in this 
subgroup. This anomaly is again likely to be a product of the limited sample size, the 
distribution of the undetermined samples, and above all, the fact that a fraction of the luminal 
A tumour samples will likely be classified as luminal B once HER2/Ki-67 status is 
determined. Indeed, incidence of metastasis in the luminal A cohort seems rather elevated 
(12). Overall survival rates could not be established here as it was not possible to obtain 
mortality data, and thus comparison with the literature cannot be achieved.  
The selection of genes to study in the q-RT-PCR was limited to those 50 genes to which AP-2 
alpha can bind. The literature did not provide specific primers for all of these genes, while 
some others did not correlate with the data available on the website. This forced a default 
selection rather than a specific selection.  
Recommendations in the literature on an appropriate threshold for determining oestrogen and 
progesterone receptor positivity vary between approximately 1% and 45% (23), depending on 
the protocol of the laboratory involved In the United States, the American Society of Clinical 
Oncology/College of American Pathologists recommend ER or PR threshold levels of 
positivity should be decreased from 10% to 1% and that ER/PR testing be standardized 
internationally (24). In the University Hospital of Lausanne this cut off point is 20 %. Some 
samples may not be classified as luminal, as exemplified by the two tumour samples tested by 
q-RT-PCR (HER3 and TN4).  These displayed expression of the ER alpha gene, but at a low 
level of ER/PR positivity (ranging from 1% to 19%), terming them ER/PR negative under 
present designation.  In clinical practice however, following the St-Gallen guidelines of 2009, 
these patients are still treated with hormonotherapy. In the follow-up to this study, decisions 
should be taken regarding which molecular subtype classification these samples are assigned. 
No significant correlation was found between the genes’ expression level and the 
pathological/clinical data. This could be due to the small sample size, troubleshooting during 
the total RNA extract experiment (e.g. presence of Rnase or Dnase, inadequate tumour mass 
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in the specimen, inadequate quantity of RNA taken from the sample and also the disparity in 
the quantity taken between the different specimens).  
Although there appeared to be some inverse proportionality between AP-2 alpha expression 
level and menopausal status, tumour size, lymphovascular invasion, lymph node metastasis, 
histological grade, mastectomy, metastasis, chemotherapy and radiotherapy, the limited size 
of the sample precluded a statistically significant correlation. 
Result of WWOX and AP-2 alpha of the q-RT-PCR showed a strong correlation, suggesting 
WWOX is directly regulated by AP-2 alpha. In fact, WWOX physically binds to AP2-alpha 
and gamma (27). WWOX is a tumour suppressor whose role has been proven in a couple of 
carcinoma types (lung, ovarian, stomach, oesophageal). Ekizoglu and al., demonstrated by 
PCR and direct sequencing that mutations in WWOX have a role in breast cancer 
pathogenesis (28). Studies have shown there was reduction of expression of WWOX in breast 
cancer, and even poor expression could be associated with triple negative molecular subtype 
(28). There remains a paucity of data on the exact frequency of WWOX expression in breast 
cancer (28). It was also suggested that WWOX could have a regulatory role in oestrogen 
receptor metabolism (29). Its interaction with AP-2 alpha needs to be determined, creating 
new molecular pathways to be explored.  
In my one month placement at the laboratory, I was able to test two samples (TN5 and LA3) 
with the PBM method. This showed that AP-2 alpha bound to a group of genes reflecting each 
of the molecular subtypes. Not enough tumour samples could be tested during my placement, 
and so there was inadequate information on Ap2 binding activity to allow correlation with 
clinical data. Limitation in time was also an issue, as learning basic laboratory skills proved 
difficult in just one month. This study is ongoing at the laboratory of Professor Mermod at 
EPFL.                                                        
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Conclusion  
 
Although the q-RT-PCR results were not significant for AP-2 alpha and for the other genes, 
this could be a product of an insufficient sample size. In that case, repeating the experiment 
with more tumour samples would increase the power of the study and in the future it may 
possible to definitively correlate the level of expression with the pattern of binding activity 
found on PBM. Interaction between AP-2 alpha and WWOX has been described here, 
however this warrants further study.  
The preliminary data from the two tumour samples analysed by protein binding microarray 
displayed the results we expected. Follow-up to the current PBM study should be performed 
with special regard for the current guidelines recognizing the need for more accurate 
classification of the samples i.e. agreement on the threshold level for oestrogen and 
progesterone receptors. Currently, work is in progress to determine HER2 and Ki-67 status.  
In conclusion, in recent years, management of breast cancer has been primarily based on the 
biology of the tumour itself, rather than the stage of the cancer. The trend toward a more 
biologic model can be noted annually in the findings of the St-Gallen consensus. This has an 
important impact in research, patient care and treatment, and this PBM study aims to further 
this development of a biologic based model of management. Indeed, by using the PBM 
method there is a hope to better describe and understand breast cancer. The role of AP-2 alpha 
as a negative prognostic indicator in cancers thought of as low risk under current 
classifications warrants further investigation. The use of PBM in this regard as a clinical tool 
may lead to better prognosis of the disease and even to new treatment development. 
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Appendix 
 
Appendix 1:  
Put the sections fixation in acetone at -20C° for 10min. Air dry and then put in a hematoxillin 
for 3 min. Rinse in tap water for 3 min while regularly changing the water. Put in an eosin 
0.25% for 30 seconds. Rinse in tap water and dH2O. Put successively for a couple of seconds 
EtOH95%, EtOH 100% and xylene. Finally mount with Eukitt on the slides. 
 
Appendix 2: 
Wizard SV Gel and PCR Clean-Up System: Gel Slice and PCR Product Preparation 
A. Dissolving the Gel Slice 
1.  Following electrophoresis, excise DNA band from gel and place gel slice in a 1.5ml 
microcentrifuge tube. 
2.  Add 10µl Membrane Binding Solution per 10mg of gel slice. Vortex and  incubate at 50–
65 C°  until gel slice is completely dissolved. 
B. Processing PCR Amplifications 
1.   Add an equal volume of Membrane Binding Solution to the PCR amplification. 
 Binding of DNA  
1.  Insert SV Minicolumn into Collection Tube. 
2.  Transfer dissolved gel mixture or prepared PCR product to the Minicolumn assembly. 
Incubate at room temperature for 1 minute. 
3.  Centrifuge at 16,000 × g for 1 minute. Discard flowthrough and reinsert Minicolumn into 
Collection Tube. 
Washing  
4.  Add 700µl Membrane Wash Solution (ethanol added). Centrifuge at 16,000 × g for 1 
minute. Discard flowthrough and reinsert Minicolumn into Collection Tube. 
5.  Repeat Step 4 with 500µl Membrane Wash Solution. Centrifuge at 16,000 × g for 5 
minutes. 
6.  Empty the Collection Tube and recentrifuge the column assembly for 1 minute with the 
microcentrifuge lid open (or off) to allow evaporation of any residual ethanol. 
Elution 
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7.  Carefully transfer Minicolumn to a clean 1.5ml microcentrifuge tube. 
8.  Add 50µl of Nuclease-Free Water to the Minicolumn. Incubate at room  temperature for 1 
minute. Centrifuge at 16,000 × g for 1 minute. 
9.  Discard Minicolumn and store DNA at 4 C° or –20 C°. 
 
Appendix 3: 
Add 1ml per tube of Trizol on frozen cells and vortex vigorously. Leave for 5 min in ambient 
temperature. Add 200ul of chloroform. Vortex for 20s and then leave for 5min in ambient 
temperature. Centrifuge for 15min at ambient temperature. In a new tube, place 500ul of 
aqueous solution and 500ul of isopropanol. Leave to rest for 10min in room temperature and 
centrifuge for 15min 4 C° 12000g. Eliminate the supernatant and add 1ml d’EtOH 70% -20 
C° to the sediment . Centrifuge for  5min at 4C 10000g. Repeat the procedure. Eliminate the 
maximum alcohol possible with a pipette and let the sediment dry at air temperature. 
Reprendre le culot dans 50ul d’eau nano-pure Rnase free+ 1ul de Rnasine. Conserve at -80 
C°. 
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